Lummy Strikes First Deal Under VC Fund Investment
This article was originally published in PharmAsia News
TVM Capital Life Science has established a new $50 million venture capital fund with investment from Chinese partner Lummy, which has already tapped the new vehicle for a licensing deal for an oncology dendritic vaccine.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.